T. Hirashima

T. Miyazawa, T. Iwasaki, K. Kawahara, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy

T. Miyazawa, M. Ohta, Hidekazu Suzuki, 2008, Surgical Endoscopy.

Radial endobronchial ultrasound with a guide sheath for diagnosis of peripheral cavitary lung lesions: a retrospective study

Hidekazu Suzuki, K. Kawahara, T. Hirashima, 2016, BMC Pulmonary Medicine.

A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102

T. Kijima, T. Hirashima, S. Minami, 2019, Internal medicine.

Re-challenge chemotherapy in patients with sensitive relapse small-cell lung cancer and interstitial lung disease.

Satomu Morita, Hidekazu Suzuki, T. Hirashima, 2019, Journal of thoracic disease.

Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2017, Anticancer research.

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1998, British Journal of Cancer.

Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer.

I. Kawase, T. Hirashima, K. Asami, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.

M. Fukuoka, I. Kawase, N. Masuda, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2013, Medical Oncology.

Carboplatin plus paclitaxel in combination with bevacizumab for the treatment of adenocarcinoma with interstitial lung diseases.

I. Kawase, Satomu Morita, Hidekazu Suzuki, 2013, Molecular and clinical oncology.

The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.

S. Akinaga, K. Muro, Y. Koh, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905.

M. Tsuboi, N. Ikeda, M. Fukuoka, 2012, Lung cancer.

Phase I and pharmacologic study of oral (E)-2′-deoxy-2′-(fluoromethylene) cytidine: on a daily × 5-day schedule

M. Fukuoka, S. Kudoh, M. Takada, 1998, Investigational New Drugs.

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study

I. Kawase, T. Kijima, Hidekazu Suzuki, 2016 .

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

T. Mitsudomi, M. Ahn, Keunchil Park, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for non-small cell lung cancer after failure of platinum-doublet chemotherapy.

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2012, Anticancer research.

Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors

Toshio Tanaka, Hidekazu Suzuki, K. Kawahara, 2020, AntiCancer Research.

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report

Satomu Morita, Hidekazu Suzuki, T. Hirashima, 2016, Respiratory medicine case reports.

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer

Y. Hosomi, H. Saka, K. Kiura, 2013, Investigational New Drugs.

Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies.

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2011, Anticancer research.

Effect of Topotecan as Second-Line Chemotherapy for Small Cell Lung Cancer Patients with Interstitial Lung Disease

I. Kawase, T. Hirashima, M. Tamiya, 2011, Journal of chemotherapy.

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer.

S. Toyooka, T. Mitsudomi, M. Satouchi, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report.

Hidekazu Suzuki, K. Kawahara, T. Hirashima, 2016, Journal of thoracic disease.

Angled forceps used for transbronchial biopsy in which standard forceps are difficult to manipulate: a comparative study.

I. Kawase, K. Matsui, K. Kawahara, 2006, Chest.

Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

S. Toyooka, Y. Yatabe, T. Mitsudomi, 2012 .

p53 status and prognosis in stage I-IIIa non-small cell lung cancer.

M. Fukuoka, A. Kubo, T. Hirashima, 1997, International journal of oncology.

Clinical significance of p53 in non-small-cell lung cancer.

I. Kawase, T. Hirashima, T. Komiya, 1999, Oncology reports.

Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2016, European journal of hospital pharmacy. Science and practice.

Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.

I. Kawase, T. Kijima, F. Imamura, 2011, Lung cancer.

Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study

Hidekazu Suzuki, T. Hirashima, Y. Samejima, 2020, Investigational New Drugs.

Outpatient Chemotherapy for Non-small-cell Lung Cancer

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2011 .

The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2013, Chinese journal of cancer.

Risk Factors of Afatinib Induced Diarrhea: A Retrospective Study

Hidekazu Suzuki, T. Hirashima, N. Okamoto, 2016 .

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

S. Kudoh, Y. Ichinose, M. Fukuoka, 2008, British Journal of Cancer.

p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.

M. Fukuoka, I. Kawase, T. Hirashima, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer

Y. Kinoshita, S. Nomura, F. Imamura, 2009, Platelets.

Nanoparticle Albumin-bound Paclitaxel+Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease.

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2015, Internal medicine.

A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma

Satomu Morita, Hidekazu Suzuki, T. Hirashima, 2019, Respiratory medicine case reports.

Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR‐mutant (Exon18:G719S) lung adenocarcinoma as a second‐line chemotherapy

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2017, Asia-Pacific journal of clinical oncology.

Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study

Y. Kogure, M. Satouchi, K. Nishio, 2014, Oncotarget.

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

H. Tanii, S. Sakajiri, Ken Kobayashi, 2012, Investigational New Drugs.

A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.

I. Kawase, S. Goya, Hidekazu Suzuki, 2012, Anticancer research.

Prognostic factors in malignant pleural mesothelioma: a retrospective study.

I. Kawase, Satomu Morita, Hidekazu Suzuki, 2012, Internal medicine.

Soluble Mesothelin-related Peptides (SMRP) as a Biomarker for Malignant Pleural Mesothelioma

M. Okada, K. Fukuoka, K. Kawahara, 2009 .

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.

Yusuke Nakamura, I. Kawase, A. Yokoyama, 2008, Lung cancer.

Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma.

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2010, Anticancer research.

Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2012, Medical Oncology.

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer

T. Sakaeda, T. Hirashima, M. Tamiya, 2019, Scientific Reports.

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

T. Yamanaka, M. Okada, A. Kubo, 2015 .

The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer.

Tesshi Yamada, I. Kawase, Hidekazu Suzuki, 2015, Anticancer research.

The effect of CYP 2 C 19 polymorphism on the safety , tolerability , and pharmacokinetics of tivantinib ( ARQ 197 ) : results from a phase I trial in advanced solid tumors

S. Akinaga, K. Muro, Y. Koh, 2013 .

Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents.

Satomu Morita, Hidekazu Suzuki, T. Hirashima, 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration

K. Uno, T. Hirashima, H. Matsuoka, 2020, medRxiv.

Skin Rash Can Be a Useful Marker for Afatinib Efficacy.

Satomu Morita, K. Iwata, Hidekazu Suzuki, 2018, Anticancer research.

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia

T. Hirashima, Y. Sakurai, Eriko Tani, 2022, Respiratory medicine case reports.

Analysis of Early Death in Japanese Patients With Advanced Non–small‐cell Lung Cancer Treated With Nivolumab

Hidekazu Suzuki, K. Kunimasa, F. Imamura, 2017, Clinical lung cancer.

Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer.

T. Nishida, T. Yamadori, Y. Shima, 2006, Cancer science.

Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial.

M. Tsuboi, H. Saka, M. Satouchi, 2021, JAMA oncology.

A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.

T. Mukohara, M. Fukuoka, S. Kudoh, 2005, Japanese journal of clinical oncology.

Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.

Hidekazu Suzuki, K. Taira, K. Takeda, 2013, Clinical lung cancer.

Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002

J. Uchida, Hidekazu Suzuki, Y. Fukuda, 2021, Investigational New Drugs.

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

K. Shimizu, Hidekazu Suzuki, T. Hirashima, 2010 .

Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors

Hidekazu Suzuki, K. Kawahara, T. Hirashima, 2020, AntiCancer Research.

Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy

T. Tada, K. Matsui, M. Hosono, 2005, International Journal of Clinical Oncology.

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

Koichi Yamazaki, Satoshi Morita, Masahiro Fukuoka, 2009, Clinical Cancer Research.

Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non‐squamous cell non‐small cell lung cancer in Japan

Hidekazu Suzuki, T. Hirashima, K. Asami, 2014, Thoracic cancer.

Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations.

T. Hirashima, K. Asami, T. Kawaguchi, 2013, Lung cancer.

Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.

Hidekazu Suzuki, T. Hirashima, T. Kawaguchi, 2016, Anticancer research.

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

Y. Ohe, H. Saka, M. Satouchi, 2017, ESMO Open.

Prognostic significance of hTERT expression in non-small cell lung cancer.

M. Fukuoka, I. Kawase, T. Nitta, 2000, International journal of oncology.

Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer.

M. Fukuoka, I. Kawase, T. Nitta, 2000, Anticancer research.

The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Toshio Tanaka, Hidekazu Suzuki, K. Kawahara, 2019, AntiCancer Research.

Impact of pneumonia on hyperactive delirium in end-stage lung cancer patients

I. Kawase, Satomu Morita, Hidekazu Suzuki, 2012, Supportive Care in Cancer.

A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer

K. Nishio, I. Okamoto, K. Takezawa, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer

Hidekazu Suzuki, A. Shintani, K. Kunimasa, 2020, AntiCancer Research.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

S. Akinaga, M. Satouchi, H. Murakami, 2013, British Journal of Cancer.

The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer

Hidekazu Suzuki, T. Hirashima, Y. Samejima, 2020, AntiCancer Research.

Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity

J. Christensen, T. Boggon, B. Halmos, 2008, Oncogene.

Clinical COVID-19 diagnostic methods: Comparison of reverse transcription loop-mediated isothermal amplification (RT-LAMP) and quantitative RT-PCR (qRT-PCR)

Toshio Tanaka, T. Hirashima, H. Matsuoka, 2021, Journal of Clinical Virology.

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.

M. Fukuoka, S. Kudoh, T. Nitta, 1993, British Journal of Cancer.

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2017, Cancer medicine.

Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non‐small cell lung cancer

Y. Horio, M. Shi, H. Tanii, 2011, Cancer science.

Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.

Masahiro Fukuoka, Tomonori Hirashima, Kazuhiko Nakagawa, 2002, Lung cancer.

Clinical evaluation of endoscopic bronchial occlusion with silicone spigots for the management of persistent pulmonary air leaks.

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2011, Internal medicine.

Endoscopic Bronchial Occlusion with Silicon Spigots for the Treatment of an Alveolar-pleural Fistula during Anti-tuberculosis Therapy for Tuberculous Empyema.

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2016, Internal medicine.

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2020, Thoracic cancer.

Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M

Satomu Morita, Hidekazu Suzuki, T. Hirashima, 2018, AntiCancer Research.

Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations

Hidekazu Suzuki, T. Hirashima, T. Kawaguchi, 2018, Investigational New Drugs.

Phase II study of erlotinib plus tivantinib ( ARQ 197 ) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI , ge fi tinib or erlotinib

T. Mitsudomi, S. Akinaga, K. Kubota, 2016 .

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed

S. Kudoh, K. Hirata, Tatsuo Kimura, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): Results of West Japan Thoracic Oncology Group trial (WJTOG0403).

S. Kudoh, Y. Ichinose, M. Fukuoka, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2015, Medical Oncology.

A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement.

I. Kawase, Hidekazu Suzuki, K. Kawahara, 2015, Internal medicine.

Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions

Yukiko Nakamura, I. Kawase, T. Nitta, 2007, International Journal of Clinical Oncology.

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

Y. Matsuda, J. Uchida, Hidekazu Suzuki, 2021, Translational lung cancer research.

Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation.

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2020, Future oncology.

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

J. Uchida, Hidekazu Suzuki, Y. Fukuda, 2019, Investigational New Drugs.

Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?

Hidekazu Suzuki, K. Kunimasa, F. Imamura, 2019, AntiCancer Research.

Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis

S. Vowler, T. Mitsudomi, K. Kiura, 2019, Cancer science.

Title Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer : updated results of the West Japan Oncology Group

N. Ikeda, H. Saka, M. Ando, 2018 .

Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.

N. Ikeda, H. Saka, M. Ando, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy

I. Kawase, K. Akazawa, Hidekazu Suzuki, 2012, Medical Oncology.

Diagnostic factors of standard bronchoscopy for small (≤15 mm) peripheral pulmonary lesions: a multivariate analysis.

I. Kawase, Hidekazu Suzuki, K. Kawahara, 2011, Internal medicine.

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2021, Scientific Reports.

Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial

T. Yamanaka, M. Okada, A. Kubo, 2016, Cancer.

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2014, Oncology letters.

Diagnostic yield of combined bronchoscopy and endobronchial ultrasonography, under LungPoint guidance for small peripheral pulmonary lesions

I. Kawase, Hidekazu Suzuki, E. Yoshida, 2013, Respirology.

Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L

H. Saka, Y. Kogure, M. Ando, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2013, Clinical lung cancer.

The Clinical Significance of the Serum Cross-Linked N-Telopeptide of Type I Collagen as a Prognostic Marker for Non-Small-Cell Lung Cancer

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2012 .

Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center study

Toshio Tanaka, Hidekazu Suzuki, T. Hirashima, 2020, Journal of Infection and Chemotherapy.

Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2015, Asia-Pacific journal of clinical oncology.

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.

M. Fukuoka, K. Tamura, M. Takada, 1996, British Journal of Cancer.

Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2017, Medicine.

Telomerase activity in endoscopically visible lung cancer.

I. Kawase, T. Nitta, Y. Takada, 2001, Anticancer research.

[Prognostic significance of alterations in telomeric repeat length in patients with pathological stage I-II non-small cell lung cancer].

I. Kawase, T. Nitta, T. Hirashima, 1998, Nihon rinsho. Japanese journal of clinical medicine.

Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19

Toshio Tanaka, T. Shioda, K. Yoshizaki, 2021, Frontiers in Medicine.

Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies

H. Saka, M. Satouchi, K. Goto, 2020, Japanese journal of clinical oncology.

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

T. Morimoto, J. Uchida, Hidekazu Suzuki, 2020, Clinical lung cancer.

Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group

T. Yamanaka, M. Fukuoka, K. Sugio, 2014, Cancer science.

Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

N. Ikeda, M. Fukuoka, H. Saka, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer.

M. Fukuoka, N. Masuda, T. Nitta, 2001, Internal medicine.

Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non–small Cell Lung Cancer: The Final Report

S. Kudoh, K. Hirata, Tatsuo Kimura, 2017, American journal of clinical oncology.

Aggressive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer with Resistance to Anti-Cancer Agents: a Case Report

T. Hirashima, Eriko Tani, T. Nishida, 2022, Haigan.

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

T. Morimoto, K. Nagata, J. Uchida, 2021, BMC cancer.

Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2018, In Vivo.

Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Hidekazu Suzuki, A. Nishitani, M. Fujishima, 2018, BMC Cancer.

Acromegaly Initially Presenting with Severe Infectious Diseases: A Case Report

T. Hirashima, Y. Sakurai, Eriko Tani, 2021, JMA journal.

Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy.

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2016, Journal of thoracic disease.

Proteomics‐based identification of α‐enolase as a tumor antigen in non‐small lung cancer

Ping He, Tomonori Hirashima, Minoru Fujimoto, 2007 .

Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2017, Anticancer research.

Usefulness of High Suction Pressure for Sufficient Tissue Collection During Endobronchial Ultrasound Guided Transbronchial Needle Aspiration

I. Kawase, Satomu Morita, Hidekazu Suzuki, 2013, PloS one.

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Y. Ohe, H. Saka, M. Satouchi, 2017, Cancer science.

Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer

I. Kawase, T. Kijima, A. Kumanogoh, 2012, Cancer Chemotherapy and Pharmacology.

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C

Y. Ohe, H. Saka, K. Yoh, 2021, Targeted Oncology.

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

T. Mitsudomi, S. Akinaga, K. Kubota, 2016, ESMO Open.

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma

Satomu Morita, Hidekazu Suzuki, T. Hirashima, 2017, Respiratory medicine case reports.

Three cases of the nodular pulmonary amyloidosis with a longterm observation.

I. Kawase, Hidekazu Suzuki, K. Matsui, 2006, Internal medicine.

Extracellular Water-to-total Body Water Ratio as an Objective Biomarker for Frailty in Lung Cancer Patients

K. Iwata, Hidekazu Suzuki, T. Hirashima, 2021, AntiCancer Research.

Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer

I. Kawase, T. Tada, K. Minakuchi, 2006, International Journal of Clinical Oncology.

Efficacy of Polaprezinc Against Chemoradiotherapy-induced Esophagitis in Lung Cancer Patients: a Retrospective Study

K. Iwata, Hidekazu Suzuki, T. Hirashima, 2017 .

Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide.

M. Fukuoka, A. Kubo, J. Takahara, 1996, Cancer research.

S. Toyooka, T. Mitsudomi, M. Satouchi, 2019 .

Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.

T. Mitsudomi, M. Ahn, Keunchil Park, 2014 .

Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2017, Anticancer research.

Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2018, AntiCancer Research.

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial

Hidekazu Suzuki, K. Kunimasa, F. Imamura, 2018, PloS one.

Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer

T. Kijima, Hidekazu Suzuki, T. Hirashima, 2017, Cancer Chemotherapy and Pharmacology.

Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP)

T. Mitsudomi, N. Sunaga, K. Sugio, 2008 .

1271PRANDOMIZED PHASE III STUDY COMPARING GEFITINIB (G) WITH ERLOTINIB (E) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED ADVANCED LUNG ADENOCARCINOMA (LA): WJOG 5108L.

M. Okada, M. Fujita, T. Nishimura, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study

I. Kawase, Hidekazu Suzuki, M. Fujishima, 2014, BMC Cancer.

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

J. Uchida, Hidekazu Suzuki, Y. Fukuda, 2019, Investigational New Drugs.

Stratification of Malignant Pleural Mesothelioma Prognosis Using Recursive Partitioning Analysis

I. Kawase, Hidekazu Suzuki, T. Hirashima, 2014, Lung.

Transformation to small cell lung cancer after first-line afatinib treatment

Satomu Morita, Hidekazu Suzuki, K. Kawahara, 2018, Respiratory medicine case reports.

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.

Y. Hosomi, M. Okada, H. Saka, 2023, Cancer science.

Serum HE4 as a diagnostic and prognostic marker for lung cancer

I. Kawase, Hidekazu Suzuki, T. Naka, 2012, Tumor Biology.

Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer

Hidekazu Suzuki, K. Kawahara, T. Hirashima, 2018, Investigational New Drugs.

OA08.05 Efficacy and Cerebrospinal Fluid Concentration of Afatinib in NSCLC Patients with EGFR Mutation Developing Leptomeningeal Carcinomatosis

Hidekazu Suzuki, T. Hirashima, M. Tamiya, 2017 .

[Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)].

K. Iwata, Hidekazu Suzuki, T. Hirashima, 2015, Gan to kagaku ryoho. Cancer & chemotherapy.

O-272 A randomized phase II study of carboplatin/gemcitabine (CG) versus vinorelbine/gemcitabine (VG) in patients (pts) with advanced Non-Small Cell Lung Cancer (NSCLC); West Japan Thoracic Oncology Group (WJTOG) 0104

M. Fukuoka, Y. Nakanishi, M. Takada, 2003 .

Correlative study of EGFR mutations or protein expressions of EGFR, phosphorylated EGFR, HER2, phosphorylated HER2 and IGFR-1 with gefitinib sensitivity in patients with non-small cell lung cancer: Results of West Japan Thoracic Oncology Group trial (WJTO)

M. Fukuoka, K. Tamura, A. Kubo, 2007 .

Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Hidekazu Suzuki, A. Nishitani, M. Fujishima, 2018, BMC Cancer.

Prognosis of small-cell lung cancer since the introduction of amrubicin

I. Kawase, Hidekazu Suzuki, K. Matsui, 2011, Medical oncology.

Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion

Y. Matsuda, Hidekazu Suzuki, F. Imamura, 2021, Investigational New Drugs.

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer

I. Kawase, T. Kijima, J. Uchida, 2013, BMC Research Notes.

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

P. Jänne, T. Mitsudomi, M. Ahn, 2015 .

Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.

M. Fukuoka, S. Kudoh, M. Takada, 1995, Japanese journal of clinical oncology.

9118 POSTER Prospective Assesment of Combined Pemetrexed and Erlotinib or Gefitinib Therapy After the Relapse to Erlotinib or Gefitinib in Patients With Advanced Non-Small Cell Lung Cancer Having an Active Epidermal Growth Factor Receptor Mutation

S. Kudoh, K. Hirata, Tatsuo Kimura, 2011 .

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

M. Satouchi, S. Morita, F. Imamura, 2018, Lung cancer.

Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).

T. Nishimura, T. Hirashima, N. Katakami, 2023, Lung cancer.

Long-term amrubicin chemotherapy for small-cell lung cancer.

I. Kawase, S. Goya, Hidekazu Suzuki, 2012, Anticancer research.

Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer

S. Imoto, T. Aoshi, T. Irie, 2022, JCI Insight.

Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non‐squamous cell non‐small cell lung cancer in Japan

Hidekazu Suzuki, T. Hirashima, K. Asami, 2014, Thoracic cancer.

The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.

Hidekazu Suzuki, F. Imamura, T. Hirashima, 2017, Anticancer research.

Transbronchial Cryobiopsy for Miliary Tuberculosis Mimicking Hypersensitivity Pneumonitis

Hidekazu Suzuki, K. Kawahara, T. Hirashima, 2020, Internal medicine.